Minimal residual disease (MRD) appears to have a strong negative predictive value for disease recurrence in children with anaplastic large cell lymphoma (ALCL). Brentuximab vedotin (BV) can be a therapeutic option for MRDpositive patients to achieve molecular remission and to decrease risk of subsequent relapse. We here report a 4-year-old child with ALCL progression during relapse treatment who received BV as a bridging therapy before haploidentical hematopoietic stem-cell transplantation, and as a maintenance therapy post-transplant alone or combined with simultaneous low dose donor-lymphocyte infusions. MRD monitoring showed a complete molecular response and reflected both BV efficiency and graft-versus-lymphoma effect.
Introduction
Despite the high remission rate in childhood anaplastic large cell lymphoma (ALCL) achievable through various conventional chemotherapy treatments, disease recurrence occurs in approximately one third of patients, without signif-icant progress over the last decade [1] [2] [3] . Nucleophosmin-anaplastic lymphoma kinase (NPM1-ALK) expressing cells can be detected in peripheral blood in around half of children with ALK-positive ALCL and are a useful tool for chemotherapy response assessment [4] . Minimal residual disease (MRD) appears to have a strong negative predictive value for disease recurrence in children with ALCL [5] .
The majority of relapsed patients are required to undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT). Low relapse rate after alloHSCT, as well as effective donor-lymphocyte infusions (DLI) provides evidence for a graftversus-lymphoma (GvL) effect [6] [7] . Incomplete immune reconstitution in the early post-alloHSCT phase, especially after haploidentical transplantation, leads to an increased risk of subsequent relapse. One of the new strategies to prevent relapse after alloHSCT is the target therapy. Brentuximab vedotin (BV), which is an antibody-drug conjugate that targets CD30, demonstrated sustained responses in patients with recurrent ALCL and had a very moderate adverse-effect profile [8] . BV has been suggested both as a bridge to alloHSCT and as a posttransplantation maintenance therapy, including combination with DLI [9] [10] [11] . The data of using BV in pediatric patients is very limited but encouraging [12] [13] [14] .
Here is a report of a child with ALCL progression during relapse treatment who received BV before and after T-cell receptor (TCR)-αβ-depleted haploidentical HSCT, alone or combined with simultaneous DLI. MRD monitoring showed a complete molecular response and reflected both BV efficiency and GvL effect. 
Case Report

Discussion
A majority of ALK-positive ALCLs express NPM1-ALK fusion gene, which is a suitable target for a minimal disease assessment. As shown previously, high number of circulating lymphoma cells at diagnosis and their slow clearance during inductive treatment multiply risk of ALCL recurrence in children [4] [5].
Our patient had high initial NPM1-ALK-level in blood, remained MRD-positive after cytoreductive prephase, and relapsed shortly after the end of the treatment in spite of therapy intensification. Moreover, we observed very short time interval between molecular relapse detection and first clinical symptoms of lymphoma recurrence. In spite of negative morphology of residual relapsed tumor and its minimal metabolic activity, patient preserved very high NPM1-ALK-expression in blood, which reflected the evidence of active ALCL and made soon-to-be lymphoma progression almost inevitable. Therefore, we found it meaningful to perform and correct our patient's treatment considering MRD data as well as PET/ CT and morphological response. In cases of limited chemosensitivity immunotherapy proves to be the rescue option. The efficiency of BV at the doses from 1.2 to 1.8 mg/kg in heavily pretreated children with ALCL was demonstrated in case reports and a small series of patients, with encouraging results [12] [14] . In our case we used BV as a monotherapy before alloHSCT and observed rapid NPM1-ALK-expressing cells clearance from blood. As our patient was highly likely to relapse into early posttransplantation, before any graft-versus-tumor effect appeared, BV was administered to prevent an early post-transplantation relapse. Retreatment with BV after alloHSCT demonstrated preserved sensitivity to BV and complete but very short-term molecular response, as rapid molecular relapse occurred after the third BV infusion. As it was previously published, retreatment with BV can induce repeated complete remission in relapsed systemic ALCL when considering combining BV with other therapeutic options [16] . Lower dose of BV (1 mg/kg) also showed its efficiency in a young child treatment with refractory ALCL, minimizing toxic effects [13] . Our patient received BV at a dose of 1.8 mg/kg before alloHSCT, which was allowed to perform transplantation during molecular remission, and at a dose of 1.2 mg/kg after alloHSCT, which was adequate to induce molecular and sustain clinical response.
AlloHSCT has curative potential as a result of the underlying GvL effect, even in patients without complete clinical or molecular response. But haploidentical HSCT implies T-lymphocyte depletion, which postpones GvL manifestation, and increases the risk of an early post-alloHSCT relapse. Combined administration of BV and DLI leads to synergistic anti-tumor effect, and at the same time decreases risk and severity of GvHD due to immunomodulating effect of BV [7] [11]. DLI can result in potentially life-threatening GvHD, while administered to specifically induce or enhance CvL efficacy. We administered very moderate doses of CD3+cells, much lower, than previously reported. And an obvious CvL effect developed after the first DLI of only 2 × 10 5 /kg and BV, resulted in rapid MRD negativity. It shows that even low doses of DLI can induct CvL effect. After 3 DLI doses, there were no clinical signs of GvHD. The girl had a good quality of life during the treatment and attended the hospital only for a therapeutic infusion. We didn't find another report of combined BV with DLI post-transplant treatment in children with ALCL.
The patient described here, failed 2 chemotherapy regimens. Administration of BV before and post alloHSCT resulted in a complete molecular response, whilst toxicity was minimal. Post-transplant efficacy should not be attributed to BV alone but rather to the combination of BV with low doses of DLI. MRD monitoring seems to be useful tool in management of children with NPM1-ALK-positive recurrent ALCL.
